Wegovy Pill vs Mounjaro: Which UK Weight Loss Treatment Is Best for You?

The Wegovy pill and Mounjaro are two prescription weight loss treatments that work through incretin hormone pathways, but they differ in how they are taken, how they work in the body and the average amount of weight loss seen in clinical studies. 

This article explains the differences between semaglutide and tirzepatide, compares their effectiveness, reviews side effects and practical considerations, and explores NHS availability to help you understand which option may be most suitable for your needs when combined with a reduced-calorie diet and increased physical activity.

In One Sentence

The Wegovy pill is a needle-free tablet containing semaglutide, while Mounjaro is a weekly injection containing tirzepatide with dual-hormone action that has shown greater average weight loss in clinical trials.

Key Takeaways

• Are the Wegovy pill and Mounjaro the same drug? 

No, the Wegovy pill contains semaglutide, while Mounjaro contains tirzepatide and works through both GIP and GLP-1 hormone pathways.

• Which one causes more weight loss? 

Clinical studies reported average weight loss of 20.2% with tirzepatide and 13.6% with oral semaglutide.

• Why is Mounjaro more effective? 

Its dual action targets both GIP and GLP-1 pathways, which may enhance appetite control and weight loss.

• What is the main practical difference? 

The Wegovy pill is a daily tablet with a fasting routine, while Mounjaro is a weekly injection that involves needles.

• Can I get either on the NHS? 

Mounjaro is being introduced through an NHS phased rollout, while access to the Wegovy pill currently relies on a private prescription.

What Is the Wegovy Pill (Oral Semaglutide)?

The Wegovy pill is an oral semaglutide treatment for weight management that was approved by the MHRA on the 11th of June 2026 [1].

Oral semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring gut hormone known as an incretin. It helps regulate appetite, reduce food cravings and increase satiety, which can support weight loss when used alongside lifestyle changes. Unlike injectable treatments, the tablet uses an absorption enhancer called SNAC to allow semaglutide to be absorbed through the stomach.

The medicine follows a titration schedule that gradually increases from 1.5mg to 4mg, then 9mg and eventually 25mg as the maintenance dose. This gradual increase is designed to improve tolerability and reduce gastrointestinal side effects.

Although semaglutide is also found in Rybelsus for type 2 diabetes, the Wegovy pill is a separate product specifically licensed for weight management [2]. The treatment was developed by Novo Nordisk and is intended for adults who meet prescribing criteria for weight management.

What Is Mounjaro (Tirzepatide)?

Mounjaro is a tirzepatide treatment that works as a dual GIP and GLP-1 receptor agonist for weight management.

Tirzepatide acts on two incretin pathways: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). By targeting both receptors, it can reduce appetite, increase satiety and slow gastric emptying. This dual mechanism is believed to contribute to its strong weight loss results.

Developed by Eli Lilly, Mounjaro is also used in type 2 diabetes management. For weight management, it is administered as a subcutaneous injection using the Mounjaro KwikPen, a multi-dose pre-filled pen. Treatment begins at 2.5mg weekly and may be increased gradually up to 15mg, with maintenance doses typically being 5mg, 10mg or 15mg [3].

In the United States, tirzepatide is also marketed for weight management under the brand name Zepbound.

Wegovy Pill vs Mounjaro: At-a-Glance Comparison

The main difference between these medicines is that semaglutide is a GLP-1 receptor agonist tablet, while tirzepatide is a dual GIP and GLP-1 receptor agonist delivered by injection.

The Wegovy pill is produced by Novo Nordisk and taken once daily as a tablet, while Mounjaro is produced by Eli Lilly and administered once weekly using a KwikPen injection pen. Oral semaglutide has a 25mg maintenance dose following titration, while tirzepatide maintenance doses range from 5mg to 15mg.

The tablet requires specific fasting rules before and after dosing, whereas Mounjaro can be administered at any time of day. Storage also differs, with tablets stored at room temperature and unopened Mounjaro pens requiring refrigeration between 2 and 8 degrees Celsius.

Clinical evidence from the OASIS 4 trial found oral semaglutide produced an average weight loss of 13.6% over 64 weeks [4]. In the SURMOUNT-5 trial, tirzepatide achieved an average weight loss of 20.2% over 72 weeks [5].

Regarding NHS availability, tirzepatide is being introduced through a phased rollout under NICE guidance, while the oral Wegovy pill is not currently NHS-funded [6].

Which Is More Effective, the Wegovy Pill or Mounjaro?

Current evidence suggests tirzepatide produces greater average weight loss than oral semaglutide.

The SURMOUNT-5 trial reported an average weight loss of 20.2% after 72 weeks with tirzepatide. By comparison, the OASIS 4 trial reported average weight loss of 13.6% after 64 weeks with oral semaglutide 25mg.

Although these results come from different studies rather than a direct head-to-head trial, the available evidence consistently shows higher average weight loss with tirzepatide. Real-world prescribing data have also found that tirzepatide users often lose more weight and achieve weight loss targets more frequently than semaglutide users [7].

Has the Wegovy pill been tested directly against Mounjaro?

No, there has not yet been a head-to-head trial comparing the Wegovy pill directly with Mounjaro.

The SURMOUNT-5 study compared tirzepatide against the Wegovy injection, which contains semaglutide, rather than against the oral tablet. However, the Wegovy injection's own trial demonstrated weight loss of 14.9%, which is comparable to the 13.6% reported for oral semaglutide [8].

Because of this therapeutic equivalence between pill and injection forms of semaglutide, researchers can make an evidence-based inference that Mounjaro would likely remain more effective than the oral formulation.

Why does Mounjaro tend to work better?

Mounjaro appears to work better because it activates both the GLP-1 receptor and GIP receptor through dual agonism.

This additive mechanism influences appetite regulation, satiety and metabolic processes through two hormone pathways rather than one. In the SURMOUNT-5 trial, more than 80% of participants lost at least 10% of body weight, while around one-third achieved losses of 25% or more.

The SURMOUNT-1 trial also reported average weight loss exceeding 20% on higher doses, which researchers attributed in part to dual incretin action [9]. Tirzepatide additionally produced greater improvements in several cardiometabolic outcomes in the same trial, including blood pressure and waist circumference [10].

"While average weight loss is higher with tirzepatide, treatment tolerability, adherence and individual suitability remain important considerations. The most effective treatment is the one that best matches a patient's clinical needs and preferences."

Daily Pill or Weekly Injection: How Do the Routines Compare?

The choice between a daily tablet and a weekly injection often depends on lifestyle fit and personal preference.

Some people prefer daily dosing because it avoids needles, while others find weekly dosing easier to remember and more convenient.

"Routine preference plays a major role in long-term adherence. A daily tablet may appeal to those seeking needle avoidance, while a weekly injection may suit those who prefer less frequent dosing. Shared decision-making with a prescriber is important."

The Wegovy Pill Routine

The Wegovy pill must be taken once daily under strict administration conditions.

It should be taken after an overnight fast of at least 8 hours. The tablet must be swallowed whole with a sip of water of up to 120ml and should not be crushed or chewed.

After taking the tablet, you must wait at least 30 minutes before eating, drinking or taking other oral medicines. These instructions help maximise absorption. A benefit for many users is that there are no needles and no refrigeration requirements.

The Mounjaro Routine

Mounjaro is administered once weekly on the same day each week.

The injection can be given at any time of day, with or without food. It is injected subcutaneously into the abdomen, thigh or upper arm, with injection site rotation recommended.

The KwikPen device is designed for self-administration, but users must be comfortable with a weekly injection routine and refrigeration requirements for storage.

Side Effects and Safety: How Do They Compare?

Both medicines commonly cause gastrointestinal side effects, particularly when treatment begins or doses are increased.

Common symptoms include nausea, diarrhoea, constipation and vomiting. These side effects are usually temporary and often improve as the body adjusts to treatment.

Wegovy Pill (Semaglutide)

Semaglutide is commonly associated with nausea and constipation.

As with other GLP-1-based medicines, patients should read the Patient Information Leaflet carefully and discuss any concerns with their prescriber. The medicine may not be suitable for people with certain contraindications, including a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2).

Mounjaro (Tirzepatide)

Tirzepatide is commonly associated with diarrhoea, nausea and other gastrointestinal symptoms.

In the SURMOUNT-5 trial, fewer participants stopped treatment because of gastrointestinal side effects with tirzepatide compared with semaglutide, with discontinuation rates of 2.7% and 5.6% respectively [5].

As with semaglutide, patients should review product information and discuss their medical history with a healthcare professional before treatment.

Storage and Travel

Storage requirements can influence which treatment feels more practical for everyday life.

The Wegovy pill can be stored at room temperature, making it straightforward for travel and daily portability.

Mounjaro pens must be kept within the cold chain before use and refrigerated between 2 and 8°C. Once in use, they may be stored below 30°C for a limited period, according to product guidance.

For people who travel frequently, room-temperature storage may be more convenient, while others may feel the weekly dosing schedule outweighs refrigeration requirements.

Which Should You Choose: The Wegovy Pill or Mounjaro?

The best treatment depends on your weight loss goals, lifestyle preferences and clinical suitability.

Both medicines can support meaningful weight loss, but they differ in administration, storage and average outcomes.

"A prescriber-led decision should consider BMI, expected weight loss, needle avoidance, storage needs, travel requirements and willingness to follow a fasting routine. Shared decision-making helps identify the most appropriate option."

Wegovy Pill Preference

The Wegovy pill may be a good option if needle avoidance is a priority.

You may prefer this treatment if you travel frequently, want a room-temperature tablet and are comfortable following a fasting routine that includes an 8-hour fast and a 30-minute wait after dosing. It may also suit people who want clinically meaningful average weight loss without using injections.

Mounjaro Preference

Mounjaro may be more suitable if your main goal is to achieve the highest average weight loss.

You may prefer a once-weekly routine rather than daily dosing and feel comfortable using a weekly injection. It may also appeal to people who meet NHS eligibility criteria as access expands through the phased rollout.

UK Availability, Cost and NHS Eligibility

Access to these treatments differs between private prescribing and NHS pathways.

NICE guidance on tirzepatide (TA1026) supports a phased NHS rollout, beginning with people who have the greatest clinical need. Access may involve specialist weight management services, including Tier 3 weight management services, depending on local arrangements.

The Wegovy pill received MHRA approval in June 2026 but is not currently funded on the NHS. NICE's appraisal of semaglutide supports NHS use of the injectable formulation within specialist services rather than the oral pill [11].

People seeking treatment privately may access medicines through an online prescription service, such as UK Meds, following an online consultation with a registered independent prescriber. If approved, dispensing is carried out through a General Pharmaceutical Council (GPhC) registered partner pharmacy. Eligibility is based on clinical decision-making, BMI and the presence of weight-related comorbidities where relevant. NICE guidance also includes ethnicity-adjusted BMI thresholds for some populations.

Frequently Asked Questions

Is Mounjaro better than the Wegovy pill?

Mounjaro produced greater average weight loss in studies, at around 20.2% versus 13.6% for the pill. However, individual suitability, storage preferences and comfort with needles remain important considerations.

Can I switch from the Wegovy pill to Mounjaro, or the other way round?

Switching may be possible under prescriber guidance. Patients are often started on the lowest dose of the new medicine to assess tolerance, and a washout period may sometimes be recommended depending on clinical circumstances.

Can I take the Wegovy pill and Mounjaro together?

No. Both are GLP-1-based medicines and should not be used together. Combining treatments could increase side-effect risk and would only be considered if specifically advised by a specialist clinician.

Is Mounjaro the same as Zepbound?

Yes. Both contain tirzepatide and are manufactured by Eli Lilly. Zepbound is the United States brand name, while Mounjaro is the brand used in the UK.

How is Mounjaro different from Ozempic?

Ozempic contains semaglutide and is primarily licensed for type 2 diabetes. Mounjaro contains tirzepatide and works through both GIP and GLP-1 pathways rather than a single hormone pathway.

Will I regain weight if I stop either medicine?

Weight regain is common after stopping any GLP-1-based medicine because appetite regulation effects reduce once treatment ends. Research found that people who stopped semaglutide regained around two-thirds of the weight they had lost within a year, highlighting the importance of long-term weight management strategies [12].

Final Thoughts From Our Clinical Team

“Both the Wegovy pill and Mounjaro can be effective options for weight management when combined with a reduced-calorie diet and regular physical activity. Mounjaro currently shows higher average weight loss and benefits from its dual-hormone action, while the Wegovy pill offers needle avoidance, room-temperature storage and a tablet-based approach. Factors such as BMI, willingness to follow a fasting routine, comfort with a weekly injection, refrigeration requirements and overall clinical suitability should all be considered during a prescriber consultation. Shared decision-making remains the best way to identify the most appropriate treatment for long-term success.”

Sources

[1] First GLP-1 tablet for weight loss approved in the UK - GOV.UK

[2] Wegovy 25 mg tablets (Reference only - not currently marketed in the UK) - Summary of Product Characteristics (SmPC) - (emc) | 102347

[3] Mounjaro KwikPen 15mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC) - (emc) | 15486

[4] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity | New England Journal of Medicine

[5] Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - NEJM

[6] Tirzepatide for managing overweight and obesity | Guidance | NICE

[7] Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study | Journal of Endocrinological Investigation

[8] Once-Weekly Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine

[9] Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine

[10] Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial | European Heart Journal Open | Oxford Academic

[11] Semaglutide for managing overweight and obesity | Guidance | NICE

[12] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Wilding - 2022 - Diabetes, Obesity and Metabolism